Stem cells for perinatal stroke

Affiliations

¹ Department of Pediatrics, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA 94158, USA.
² Department of Pediatrics, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA 94158, USA; Department of Neurology, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA 94158, USA. Electronic address: donna.ferriero@ucsf.edu.

Comment

Fernando Gonzalez et al. Lancet Neurol. 2022 Jun.

. 2022 Jun;21(6):497-499.

doi: 10.1016/S1474-4422(22)00142-9.

¹ Department of Pediatrics, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA 94158, USA.
² Department of Pediatrics, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA 94158, USA; Department of Neurology, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA 94158, USA. Electronic address: donna.ferriero@ucsf.edu.

No abstract available

Conflict of interest statement

DF declares grant support from the US National Institutes of Health and book royalties from Elsevier. FG declares no competing interests.

Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
Baak LM, Wagenaar N, van der Aa NE, Groenendaal F, Dudink J, Tataranno ML, Mahamuud U, Verhage CH, Eijsermans RMJC, Smit LS, Jellema RK, de Haan TR, Ter Horst HJ, de Boode WP, Steggerda SJ, Prins HJ, de Haar CG, de Vries LS, van Bel F, Heijnen CJ, Nijboer CH, Benders MJNL. Baak LM, et al. Lancet Neurol. 2022 Jun;21(6):528-536. doi: 10.1016/S1474-4422(22)00117-X. Lancet Neurol. 2022. PMID: 35568047 Clinical Trial.